Stockscreener 앱 받기
0.5697
2.11%
-0.0123
전일 마감가:
$0.582
열려 있는:
$0.5745
하루 거래량:
6,140
Relative Volume:
0.03
시가총액:
$55.13M
수익:
$1.29M
순이익/손실:
$-29.87M
주가수익비율:
-1.5825
EPS:
-0.36
순현금흐름:
$-14.70M
1주 성능:
-5.83%
1개월 성능:
-9.57%
6개월 성능:
-16.17%
1년 성능:
-36.70%
1일 변동 폭
$0.5629
$0.582
1주일 범위
$0.55
$0.6284
52주 변동 폭
$0.4301
$1.02
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.5697 | 55.13M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
516.75 | 195.34B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
208.66 | 149.60B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
119.20 | 33.84B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
413.04 | 33.52B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
183.79 | 32.24B | 15.41B | 1.37B | 2.11B | 7.50 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VolitionRx expands cancer test deal with Fujifilm Vet Systems By Investing.com - Investing.com Australia
VolitionRx extends Nu.Q Vet Cancer Test automation agreement with Fujifilm - TipRanks
Volition Signs First Ever Nu.Q Vet Cancer Test Automation Agreement With Fujifilm Vet Systems - Marketscreener.com
VolitionRx Signs Canine Cancer Test Automation Deal With Fujifilm Vet Systems -March 13, 2025 at 09:07 am EDT - Marketscreener.com
Volition's Game-Changing Cancer Test for Dogs Goes Automated with Fujifilm Deal - StockTitan
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs - Yahoo Finance
VolitionRx’s (VNRX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time - Yahoo Finance
VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
VolitionRX Ltd. to Host Earnings Call - ACCESS Newswire
VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - Defense World
Examining the Potential Price Growth of VolitionRX Ltd (VNRX) - Knox Daily
Analyzing IDEXX Laboratories (NASDAQ:IDXX) and VolitionRx (NYSE:VNRX) - Defense World
VolitionRX Ltd (VNRX) Shares Up Despite Recent Market Volatility - The News Heater
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 - Yahoo Finance
Game-Changing Sepsis Detection: 971-Patient Study Validates Revolutionary Blood Test - StockTitan
Inflammatix’s Triverity scores FDA clearance for ER sepsis test - BioWorld Online
Veterinary Oncology Diagnostics Market Size Report, 2030 - Grand View Research
D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx reports expanded global reach in 2024 - Investing.com India
VolitionRx's Nu.Q® Vet Cancer Test Hits Major Milestone: 110,000+ Tests Sold Across 20 Countries - StockTitan
Competition ticks up to reset the clock for sepsis - BioWorld Online
VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock By Investing.com - Investing.com Nigeria
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Australia
Volitionrx director Innes buys $99,999 in common stock - Investing.com India
VolitionRx chief scientific officer Micallef acquires $24,999 in stock By Investing.com - Investing.com Australia
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock - Investing.com
SEC Form 424B5 filed by VolitionRX Limited - Quantisnow
Form 424B5 VOLITIONRX LTD - StreetInsider.com
VolitionRx announces pricing of up to $1.9M registered direct offering - MSN
VolitionRx announces $1.9 million stock sale By Investing.com - Investing.com Australia
VolitionRx Secures $1.9M Financing with Insider Backing, Includes Strategic Warrant Package - StockTitan
VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs. - Zacks Small Cap Research
VolitionRx: Big EU Trials On Deck - Investing.com
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey
VolitionRX: Q3 Earnings Snapshot - New Haven Register
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
VolitionRx Posts Strong Q3 Growth and Strategic Advances - TipRanks
Lagoda Investment Management's Strategic Acquisition in Volition - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in VolitionRX Ltd - GuruFocus.com
VolitionRX Ltd Reports Q3 Revenue of $475,000, Missing Estimates of $0.65 Million - GuruFocus.com
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.53%
0.15%
자본화:
|
볼륨(24시간):